10-Q: Kaya Holdings Reports Wider Loss Amid Psychedelic Shift

Kaya Holdings, Inc. reported a significantly wider net loss for Q2 2025, driven by increased derivative liabilities and early-stage psychedelic business development, despite exiting its cannabis retail operations.

Summary

• Kaya Holdings, Inc. (KAYS) reported a net loss attributable to the company of $4,113,088 for the six months ended June 30, 2025, a substantial increase from the $682,600 net loss for the same period in 2024.
• The company's working capital deficiency worsened to $12,008,394 as of June 30, 2025, compared to $8,035,323 at December 31, 2024.
• Derivative liabilities significantly increased to $5,827,706 at June 30, 2025, from $2,497,275 at December 31, 2024, primarily due to new convertible notes and common stock volatility.
• KAYS has fully transitioned out of its U.S. cannabis retail business (MJAI), which is now classified as a discontinued operation, and is focusing on psychedelic treatment facilities.
• The company launched 'The Sacred Mushroom,' a psilocybin treatment center in Portland, Oregon, in August 2024, and began administering treatments on July 5, 2024.
• Net sales from continuing operations (psychedelic business) were $17,149 for the six months ended June 30, 2025, compared to $0 in the prior year period.
• Weighted average common shares outstanding increased significantly to 42,664,501 for the six months ended June 30, 2025, from 22,172,835 in the prior year, indicating substantial dilution.
• The company's disclosure controls and procedures were deemed not effective as of June 30, 2025, with material weaknesses identified in internal control over financial reporting.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with a significantly widened net loss, increased working capital deficiency, and substantial derivative liabilities. While the pivot to psychedelics and initial revenue generation are positive, they are heavily overshadowed by the going concern doubt, internal control weaknesses, and ongoing need for capital raises, indicating high risk and poor financial health.

Positives

• Initiated revenue generation from continuing operations (psychedelic business) with $17,149 in net sales for the six months ended June 30, 2025, compared to zero in the prior year.
• Successfully obtained a license from the Oregon Health Authority (OHA) in April 2024 to operate 'The Sacred Mushroom' psilocybin treatment center in Portland, Oregon.
• Began administering psilocybin treatments at 'The Sacred Mushroom' on July 5, 2024, marking a significant operational milestone in the new business segment.
• Reduced cash used in total operating activities to $391,956 for the six months ended June 30, 2025, from $469,118 in the prior year, indicating a slight improvement in operational cash burn.
• Ceased operations of the former retail marijuana business (MJAI), eliminating losses from discontinued operations, which decreased from $121,238 in 2024 to $1,123 in 2025.

Negatives

• Net loss attributable to Kaya Holdings, Inc. significantly widened to $4,113,088 for the six months ended June 30, 2025, from $682,600 in the prior year period.
• Working capital deficiency increased substantially to $12,008,394 as of June 30, 2025, from $8,035,323 at December 31, 2024.
• Derivative liabilities more than doubled to $5,827,706 at June 30, 2025, from $2,497,275 at December 31, 2024, primarily due to new convertible notes and stock price volatility.
• Weighted average common shares outstanding increased by over 90% to 42,664,501, indicating significant shareholder dilution.
• Interest expense from continuing operations increased to $401,300 for the six months ended June 30, 2025, from $349,893 in the prior year, reflecting additional debt.
• Accrued interest, current, rose to $3,395,249 at June 30, 2025, from $3,005,107 at December 31, 2024.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025, with identified material weaknesses in internal control over financial reporting.
• The company is 'totally dependent on its ability to raise capital' and faces substantial doubt about its ability to continue as a going concern.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring net losses and a significant working capital deficiency.
• Dependence on the ability to raise additional capital through equity and/or debt securities, with no assurance of success on commercially reasonable terms.
• Uncertainty associated with the commercialization and ultimate success of the new psychedelic treatment business.
• Significant competition in both the legal marijuana and psychedelic medicine sectors from companies with greater experience, industry contacts, and financial resources.
• Regulatory risks related to psilocybin, which is currently illegal under Federal Law despite state-level legalization, potentially exposing the company to substantial liability.
• Historical tax risks under Section 280E of the Internal Revenue Code for former cannabis operations, which disallows most operating expense deductions for businesses trafficking in controlled substances.
• Material weaknesses in internal control over financial reporting, including the lack of an audit committee, insufficient segregation of duties, and inadequate controls over related party transactions.
• Evolving interpretations of federal, state, and local laws and regulations governing the legal marijuana and psychedelic industries, which could require substantial compliance costs or disrupt business.
• Uncertainty regarding the timing and outcome of regulatory approvals for the sale of the OLCC marijuana retail license, which impacts the release of $75,000 in escrowed funds.

Future Outlook

Management believes that further proceeds from anticipated financing transactions, combined with existing and projected revenues, will significantly alleviate the company's financial difficulties and meet working capital needs for 12 to 18 months. The company expects to launch a new website by the end of August 2025, featuring online sign-ups for lower-dose group psilocybin events, with 19 such events targeted for September 2025. The company also expects to enroll additional psilocybin licensee candidates to bolster its ranks of OHA Licensed Psilocybin Facilitators.

Management Comments

• "I would say at this stage the research is showing that in safe settings, this provides relief from debilitating mental health problems for some people." (Quoting Alan Davis, a neuroscience researcher, regarding psilocybin's potential)
• "Our facility offers a superior setting, broader activity and treatment options with pricing at or near the lower range, thereby enabling us to deliver a superior treatment experience at a much lower price than the competition, while still achieving profitability."
• "Management believes that further proceeds expected to be received from financing transactions that it is seeking to enter into, combined with existing and anticipated revenues, will alleviate the Company’s financial difficulties to a significant extent and will allow the Company to meet its anticipated working capital needs for a period of between twelve and eighteen months from the date of this report."

Industry Context

Kaya Holdings is navigating a significant strategic pivot from the highly regulated and federally illegal U.S. cannabis market to the nascent but rapidly growing psychedelic medicine sector. While the U.S. cannabis market faces federal hurdles like Section 280E, the psychedelic industry, particularly psilocybin, is gaining traction with states like Oregon and Colorado establishing regulatory frameworks for therapeutic use. The company's 'The Sacred Mushroom' facility positions it as an early mover in this emerging field, aiming to capitalize on the growing evidence of psychedelics' potential for treatment-resistant mental health disorders. This shift aligns with broader trends of medical innovation and destigmatization of psychedelics, but also exposes the company to new regulatory uncertainties and intense competition from both established pharmaceutical companies developing synthetic compounds (e.g., Compass Pathways, ATAI Life Sciences, Cybin) and other treatment providers.

Comparison to Industry Standards

• The company positions 'The Sacred Mushroom' as offering a superior setting and broader treatment options at a lower price point compared to competitors, aiming for profitability. Specific comparable companies or projects are not detailed beyond mentioning 'Compass Pathways, ATAI Life Sciences, and Cybin' as developers of synthetic psilocybin, implying a focus on the delivery aspect rather than drug development.
• Oregon and Colorado are the only two states with legalized psilocybin within a regulatory framework, with Oregon being the more mature market. The Sacred Mushroom's operation in Portland, Oregon, places it in a leading state for regulated psilocybin access.
• The company's use of 'The Sacred Mushroom' as a practicum site for a Portland, Oregon training program approved by the Colorado Psilocybin Licensing Program suggests an effort to align with emerging industry training and licensing standards across states.

Corporate Governance

Legal Proceedings

• Reached a settlement agreement with P3 Distributing L.L.C. on October 17, 2024, requiring monthly payments of $300 for 18 months and a balloon payment of $11,779, totaling $17,179. The lawsuit will be dismissed without prejudice if payments are timely.

Related Party Transactions

• A $250,000 non-convertible note to an affiliated shareholder, originally part of a Debt Modification Agreement from January 2, 2014, was extended until December 31, 2027, with 0% interest.
• Accrued compensation of $727,273 owed to Tudog International Consulting, Inc. (providing CEO services through Craig Frank, a related party) and BMN Consultants, Inc. (providing business development services), deferred until December 1, 2026. No additional accruals since January 1, 2025.
• Issued 1,000,000 shares of common stock to FDT Oregon 1 LLC owners, who are also related parties, on September 5, 2024, to acquire the remaining 51% equity interest of FDT Oregon 1 LLC.
• Fifth Dimension Therapeutics (FDT) received a $50,000 loan from Robert L. Pope and Lorinda J. Pope on June 9, 2025, which includes a 3% ownership interest in FDT for the lenders. The transfer of membership interest was still in process as of June 30, 2025.

Stakeholder Impact

• **Shareholders:** Significant dilution due to increased weighted average common shares outstanding and potential future dilution from convertible debt. Negative impact from widening net losses and going concern doubt. Potential upside from the new psychedelic business if successful.
• **Creditors:** Increased total liabilities and derivative liabilities, indicating higher financial risk. Convertible debt holders have price protection mechanisms, potentially benefiting from stock price declines.
• **Employees/Contractors:** Shifted from salaried workers to independent contractors at 'The Sacred Mushroom' in April 2025, impacting employment stability for some.
• **Customers (Psychedelic Treatment):** The opening of 'The Sacred Mushroom' provides new access to psilocybin treatments in a regulated environment, potentially offering therapeutic benefits for mental health conditions.
• **Regulatory Bodies:** The company's operations in both cannabis (historically) and psychedelics are subject to complex and evolving state and federal regulations, requiring ongoing compliance and oversight.

Next Steps

• Launch a new website by the end of August 2025, featuring online sign-ups for lower-dose group psilocybin events.
• Offer 19 lower dose group psilocybin events to the Portland Community in September 2025.
• Enroll additional potential licensee candidates to bolster ranks of OHA Licensed Psilocybin Facilitators.
• Obtain regulatory approvals for the sale of the OLCC marijuana retail license to release $75,000 from escrow.
• Secure project financing and final license approval from Greek government authorities for Kaya Farms Greece's medical cannabis projects.
• Address material weaknesses in internal control over financial reporting, including establishing an audit committee and improving segregation of duties and related party transaction controls.
• Seek additional capital through private offerings of equity and/or debt securities to fund operations and expansion.

Key Dates

Recommendation

Kaya Holdings, Inc. faces severe financial challenges, including a significantly widened net loss of over $4.1 million for the six months ended June 30, 2025, and a working capital deficiency exceeding $12 million. The company explicitly states 'substantial doubt about its ability to continue as a going concern' and is 'totally dependent on its ability to raise capital.' The substantial increase in derivative liabilities and weighted average shares outstanding indicates significant dilution and financial instability. While the pivot to psychedelic treatments and the opening of 'The Sacred Mushroom' represent a strategic shift, the financial metrics are deteriorating rapidly, and the company's internal controls are deemed ineffective with material weaknesses. These factors present an extremely high-risk profile, making the stock a strong sell for any seasoned investor or institution.

Keywords

Psychedelic Treatment, Psilocybin, Mental Health, Cannabis Industry, SEC Filing, Form 10-Q, Kaya Holdings, KAYS, Fifth Dimension Therapeutics, The Sacred Mushroom, Oregon Health Authority, Convertible Debt, Derivative Liabilities, Going Concern, Working Capital Deficiency, Corporate Governance, Internal Controls